Merz Pharma GmbH & Co. KGaA
Merz Pharma GmbH & Co. KGaA, commonly referred to as Merz, is a leading global healthcare company headquartered in Frankfurt, Germany. Founded in 1908, Merz has established a strong presence in the pharmaceutical and medical aesthetics industries, focusing on innovative solutions for neurological disorders, dermatology, and aesthetic medicine. With a commitment to research and development, Merz offers a diverse portfolio of products, including the renowned Xeomin® for neuromodulation and Belotero® for dermal fillers. These offerings are distinguished by their unique formulations and efficacy, catering to both healthcare professionals and patients. Merz has achieved significant milestones, including expansion into key international markets, solidifying its position as a trusted name in the healthcare sector. The company continues to drive advancements in patient care, making it a notable player in the global pharmaceutical landscape.
DitchCarbon Score
How does Merz Pharma GmbH & Co. KGaA's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Merz Pharma GmbH & Co. KGaA's score of 22 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Merz Pharma GmbH & Co. KGaA's reported carbon emissions
In 2023, Merz Pharma GmbH & Co. KGaA reported total carbon emissions of approximately 156,013,000 kg CO2e, with emissions distributed across various scopes: 501,000 kg CO2e from Scope 1, 431,000 kg CO2e from Scope 2, and a significant 156,013,000 kg CO2e from Scope 3. Notably, the Scope 3 emissions included 32,226,000 kg CO2e from purchased goods and services and 2,198,000 kg CO2e from waste generated in operations. In 2022, the company recorded total emissions of about 143,031,000 kg CO2e, with Scope 1 emissions at 475,000 kg CO2e and Scope 2 emissions at 421,000 kg CO2e. The Scope 3 emissions were notably high, reflecting the impact of business travel, employee commuting, and upstream transportation. For 2021, Merz reported total emissions of around 44,850,000 kg CO2e, with Scope 1 emissions at 204,000 kg CO2e and Scope 2 emissions at 210,000 kg CO2e. The Scope 3 emissions were significantly higher, indicating a substantial carbon footprint from purchased goods and services. Despite these figures, Merz Pharma has not publicly committed to specific reduction targets or initiatives, as indicated by the absence of documented reduction targets or climate pledges. The company continues to assess its carbon emissions and may implement strategies to address its environmental impact in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | |
|---|---|---|---|
| Scope 1 | 204,000 | 000,000 | 000,000 |
| Scope 2 | 210,000 | 000,000 | 000,000 |
| Scope 3 | 44,850,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Merz Pharma GmbH & Co. KGaA is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
